Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Abstract Subjects with the rare autosomal dominant disease Hereditary Hemorrhagic Telangiectasia (HHT) may develop medical conditions that require antithrombotic therapy (AT). However, safety of AT is uncertain in these patients and the only data currently available derive from retrospective analyse...

Full description

Bibliographic Details
Main Authors: Eleonora Gaetani, Fabiana Agostini, Angelo Porfidia, Igor Giarretta, Daniela Feliciani, Luigi Di Martino, Annalisa Tortora, Antonio Gasbarrini, Roberto Pola, on behalf of the Multidisciplinary Gemelli Group for HHT
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Orphanet Journal of Rare Diseases
Online Access:https://doi.org/10.1186/s13023-019-1278-z

Internet

https://doi.org/10.1186/s13023-019-1278-z

Similar Items